Company intelligence / Profile preview
Kanaph Therapeutics
Seoul, Seoul, South Koreakanaphtx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Kanaph Therapeutics develops next-generation therapeutics for oncology and autoimmune diseases using bi-specific antibodies, small molecules, and bispecific Fc-fusion proteins. Their lead assets target immuno-stimulatory pathways in the tumor microenvironment or inhibit the alternative complement pathway in autoimmune conditions. The company’s pipeline remains largely preclinical with a focus on innovative immune-modulating approaches.
- Therapeutic areas
- OncologyPulmonologyEndocrinologyImmunology
- Modalities
- Bi-specific antibodiesSmall moleculesBispecific Fc-fusion proteinsAntibody drug conjugates (ADC)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Kanaph Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kanaph Therapeutics.